In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

WATERTOWN, Mass., August 21, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage ...

Enanta (ENTA) announced that it has filed suit in the Unified Patent Court of the European Union against Pfizer (PFE) and certain of its ...

Enanta will host a conference call and webcast today at 4:30 p.m. ET. The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta’s website.

Enanta Q2, 2022 Earnings Presentation (ir.enanta.com) Since its 2017 approval, Glecaprevir generated royalties totaling $722 million per Enanta's fiscal year ending 09/2021 10-K.

Enanta argued that symptom improvement was similar for both antivirals. EDP-235 could be developed and tested in several COVID-related indications, such as long COVID or as a prophylaxis, Luly said.

Enanta will not be holding a conference call with today’s quarterly update. The company will provide its next update with the release of the EDP-323 challenge study results, expected in late ...

Enanta Pharmaceuticals Inc., (Nasdaq: ENTA), whose lead drug candidate is in late-stage trials for hepatitis C, has received a $9.2 million boost for its preclinical program focused on a new form ...